Designing novel inhibitors against falcipain-2 of Plasmodium falciparum

Bioorg Med Chem Lett. 2018 May 15;28(9):1566-1569. doi: 10.1016/j.bmcl.2018.03.058. Epub 2018 Mar 22.

Abstract

Coumarin containing pyrazoline derivatives have been synthesized and tested as inhibitors of in vitro development of a chloroquine-sensitive (MRC-02) and chloroquine-resistant (RKL-2) strain of Plasmodium falciparum and in vivo Plasmodium berghei malaria. Docking study was also done on cysteine protease falcipain-2 which showed that the binding pose of C-14 molecule and epoxysuccinate, inhibitor of falcipain-2, binds in the similar pattern. The most active antimalarial compound was 3-(1-benzoyl-5-(4-flurophenyl)-4,5-dihydro-1H-pyrazol-3yl)-7-(diethyamino)-2H-chromen-2-one C-14, with an IC50 of 4.21 µg/ml provided complete protection to the infected mice at 24 mg/kg X 4 days respectively.

Keywords: Coumarin; P. falcipaprum; Pyrazoline.

MeSH terms

  • Animals
  • Antimalarials / chemical synthesis
  • Antimalarials / chemistry
  • Antimalarials / pharmacology*
  • Coumarins / chemistry
  • Coumarins / pharmacology*
  • Cysteine Endopeptidases / metabolism*
  • Dose-Response Relationship, Drug
  • Drug Design*
  • Malaria, Falciparum / drug therapy
  • Mice
  • Molecular Docking Simulation
  • Molecular Structure
  • Parasitic Sensitivity Tests
  • Plasmodium falciparum / chemistry
  • Plasmodium falciparum / drug effects*
  • Pyrazoles / chemical synthesis
  • Pyrazoles / chemistry
  • Pyrazoles / pharmacology*
  • Structure-Activity Relationship

Substances

  • Antimalarials
  • Coumarins
  • Pyrazoles
  • coumarin
  • Cysteine Endopeptidases
  • falcipain 2